Advancements with Novel Treatment Approaches in CLL

Opinion
Video

A panel of oncology experts discuss recent advancements surrounding novel therapies for CLL, exploring their potential impact on future treatment paradigms.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
3 Things You Should Know About Hemolytic Anemias

3 Things You Should Know About Hemolytic Anemias

Catherine M. Broome, MD;Sigbjørn Berentsen, MD, PhD;Caroline Piatek, MD;Ilene Ceil Weitz, MD
December 20th 2024
Article

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.

FDA Accepts NDA for Avatrombopag in Pediatric Thrombocytopenia

Roman Fabbricatore
December 17th 2024
Article

Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

Ponatinib-Related Toxicity Management in ALL/CML Improves Over Time

Jonah Feldman
December 14th 2024
Article

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

Selinexor Combo Shows Activity in Myelofibrosis Spleen Responses, Symptoms

Morgan Bayer
December 13th 2024
Article

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.